NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises - Warrants exercised at $6 per share - Extends cash runway through Q3 2023 . | March 25, 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa. | March 21, 2022